Impact of Protamine Dose Reduction on Platelet Aggregation After Extracorporeal Circulation for Minimally Invasive Aortic Valve Replacement Surgery

Status

Not yet recruiting

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06254404

Enrollment

Registered

2024-02-12

Start date

2024-03-15

Completion date

2024-10-01

Last updated

2024-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Protamine Adverse Reaction, Protamine Dose

Brief summary

Determining the minimum effective dose of protamine after extracorporeal circulation for mini-sternotomy aortic valve replacement surgery.

Interventions

DRUGLow dose protamine

Administration of 70% of the normal dose of protamine

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Mini-sternotomy aortic valve replacement surgery * Major patients

Exclusion criteria

* Hypersensitivity to protamine * Coagulation Abnormalities * Heparin allergy * Pregnant women * Jehovah's Witnesses

Design outcomes

Primary

Measure	Time frame
Minimum effective dose of protamine after extracorporeal circulation. A bottom-up and top-down method will define CP 50.	24 hours

Contacts

Primary ContactBenjamin Javillier, MD

javillier.benjamin@hotmail.com43667180

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026